DR RX LTD

Company Registration Number:
10591116 (England and Wales)

Unaudited abridged accounts for the year ended 31 January 2024

Period of accounts

Start date: 01 February 2023

End date: 31 January 2024

DR RX LTD

Contents of the Financial Statements

for the Period Ended 31 January 2024

Balance sheet
Notes

DR RX LTD

Balance sheet

As at 31 January 2024


Notes

2024

2023


£

£
Called up share capital not paid: 1 1
Fixed assets
Intangible assets:   0 0
Tangible assets: 3 533,200 202,365
Investments: 4 299,299 177,474
Total fixed assets: 832,499 379,839
Current assets
Stocks: 500,430 442,300
Debtors:   127,888 28,500
Cash at bank and in hand: 15,000 3,200
Investments:   55,680 23,425
Total current assets: 698,998 497,425
Creditors: amounts falling due within one year:   (85,543) (45,332)
Net current assets (liabilities): 613,455 452,093
Total assets less current liabilities: 1,445,955 831,933
Creditors: amounts falling due after more than one year:   (53,887) (38,268)
Provision for liabilities: (10,000) 0
Total net assets (liabilities): 1,382,068 793,665
Capital and reserves
Called up share capital: 1 1
Share premium account: 352,879 216,500
Other reserves: 133,739 133,739
Profit and loss account: 895,449 443,425
Shareholders funds: 1,382,068 793,665

The notes form part of these financial statements

DR RX LTD

Balance sheet statements

For the year ending 31 January 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 10 October 2024
and signed on behalf of the board by:

Name: T EMME
Status: Director

The notes form part of these financial statements

DR RX LTD

Notes to the Financial Statements

for the Period Ended 31 January 2024

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

DR RX LTD

Notes to the Financial Statements

for the Period Ended 31 January 2024

2. Employees

2024 2023
Average number of employees during the period 4 4

DR RX LTD

Notes to the Financial Statements

for the Period Ended 31 January 2024

3. Tangible Assets

Total
Cost £
At 01 February 2023 202,365
Additions 330,835
At 31 January 2024 533,200
Net book value
At 31 January 2024 533,200
At 31 January 2023 202,365

DR RX LTD

Notes to the Financial Statements

for the Period Ended 31 January 2024

4. Fixed investments

720832